Xencor doses first subject in first-in-human study of XmAb942

Xencor (XNCR) announced that it has initiated dosing of healthy volunteers in the first-in-human study of XmAb942, an investigational high-potency extended half-life anti-TL1A antibody. Xencor continues to expect initial data from the ongoing study during the first half of 2025.